Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The target 'Pathogenic bacteria targeted by RUDN bacteriophage complex' refers to a specific group of bacterial pathogens, including Staphylococcus, Streptococcus, Proteus, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli, which are susceptible to lytic phage cocktails studied at RUDN University (Peoples' Friendship University of Russia) (RUDN University, 2023). These bacteria are major drivers of pyoinflammatory diseases such as wound infections, respiratory tract infections, and sepsis (Microgen, 2022). The RUDN bacteriophage complex (often associated with the commercial 'Complex Bacteriophage' or 'Pyobacteriophage') targets these organisms by binding to specific surface receptors and initiating a lytic cycle that results in bacterial cell death (NIH, 2021). This approach is a critical area of research for addressing multi-drug resistant (MDR) infections where traditional antibiotics fail (PubMed, 2020). However, therapeutic challenges include the potential for bacteria to develop phage resistance and the risk of systemic inflammatory responses due to the release of endotoxins during rapid bacterial lysis (StatPearls, 2023).
Bacterial cell lysis via the lytic cycle of bacteriophages, involving adsorption to surface receptors, genome injection, and host cell hijacking.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic bacteria (RUDN bacteriophage complex targets).